Are Dementia Caregivers Trained in Cannabis Administration?

PostedMarch 12, 2026

UpdatedMarch 12, 2026

ByMy Patient Advice

Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

As medical cannabis becomes more discussed in the UK, questions are emerging about who is responsible for administering it safely, especially in dementia care. Families, carers, and residential home staff play vital roles in supporting medication use, but are they trained to handle cannabis-based products? The answer is that formal caregiver training remains limited, and cannabis administration should only occur under medical supervision.

The Current Landscape

Cannabis-based medicinal products (CBPMs) can legally be prescribed by specialist doctors in the UK for certain conditions such as multiple sclerosis, severe epilepsy, and chemotherapy-related nausea. However, dementia is not an approved indication. According to NHS England, any use in dementia care would be off-label and must involve close specialist oversight.

As a result, there is no national caregiver training programme for cannabis administration in dementia. Most existing training focuses on general medicine management, not the unique handling, storage, or dosing of cannabinoid products.

What The Evidence Suggests

A 2025 Age and Ageing review noted that older adults using medically supervised cannabis benefitted most when carers were actively involved in symptom monitoring and medication adherence (Age and Ageing, 2024). However, it found that carers often lacked access to reliable education about safe product handling, side-effect recognition, or when to seek medical advice.

Similarly, the Alzheimer’s Society advises that untrained caregivers should not administer cannabis-based products without professional guidance, warning that improper dosing or product confusion (for example, using high-THC oils instead of CBD) can increase the risk of sedation or falls.

Clinical And Ethical Considerations

Caregivers have ethical and legal responsibilities when supporting medicine administration. In dementia care settings, this means ensuring informed consent, accurate record-keeping, and immediate reporting of side effects. Because cannabis affects the central nervous system, untrained administration can pose additional risks such as confusion or over-sedation.

NICE guidance (NG97) reinforces that cannabinoids should not be used for behavioural or cognitive symptoms in dementia and that any administration should be under specialist review (NICE, 2023).

Clinical Bottom Line

There is no national caregiver training for cannabis administration in dementia.

Carers should never give cannabis products without explicit medical instruction.

Specialist monitoring is essential to prevent confusion, sedation, or falls.

Education should focus on recognising side effects and ensuring safe storage.

Educational Context: AlleviMed

AlleviMed provides educational information about the legal and clinical frameworks for medical cannabis use in the UK. It helps families understand how prescription products are managed, stored, and reviewed under professional supervision. Although dementia is not an approved indication, AlleviMed’s materials promote safe, informed participation for caregivers and patients.

Takeaway

Dementia caregivers are not formally trained to administer cannabis, and unsupervised use can carry serious risks. Safe practice depends on specialist oversight, proper documentation, and clear communication between families and clinicians. Any introduction of cannabis into dementia care should prioritise patient safety, informed consent, and evidence-based monitoring.

Julia Sutton, MSc

Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Clarissa Morton, PharmD

Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy.